Evidence map›Paper›PMID 40094786›Full record

ArticleScience progress

A study on the molecular mechanism of cardiac protection of procarboxylpeptidase in MIRI rats based on the NLRP3 signaling pathway.

Luxiao He, Youfa Qin, Qiuping Lu, Ye Luo

Abstract read
In one paragraph

Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Luxiao HeSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China.ORCID 0009-0009-7089-8956
Youfa QinSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
Qiuping LuDepartment of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China.
Ye LuoDepartment of Clinical Pharmacy, The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectiveTo investigate the way in which prolylcarboxypeptidase (PRCP) protects against myocardial ischemia-reperfusion injury (MIRI) and the mechanisms that underlie it.MethodA surgical ligation of the coronary artery was adopted to establish a myocardial ischemia-reperfusion model in male SD rats. Thirty-six rats were randomly divided into six groups: Normal group, Sham group, MIRI model group, empty vector (MIRI + EZ.null) group, PRCP overexpression (MIRI + PRCP) group, and nicorandil (MIRI + Nic) group, with 6 rats in each group. The rats received an injection of PRCP's adeno-associated virus 9 (AAV9) through the tail vein 3 weeks prior to the modeling.ResultsCompared with the Normal and Sham groups, the expression levels of NOD-like receptor thermal protein domain-associated protein 3 (NLRP3), Caspase-1, IL-18, IL-1β, and GSDMD in the MIRI group and MIRI + EZ-null group were significantly increased (

Indexed as

CarboxypeptidasesMyocardial Reperfusion InjuryNLR Family, Pyrin Domain-Containing 3 ProteinSignal TransductionAnimalsApoptosisDisease Models, AnimalInterleukin-18Interleukin-1betaMaleMyocardiumRatsRats, Sprague-DawleyCarboxypeptidasesInterleukin-18Interleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratinflammationmyocardial ischemia-reperfusion injury (MIRI)NLRP3Prolylcarboxypeptidasepyroptosis

Identifiers

PMID40094786
PMCPMC11915547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.